A new biomarker for fibrosis in DMD

The fibrosis constantly observed in the muscle of patients suffering from Duchenne muscular dystrophy (DMD) remains largely an enigma and is not easily accessible to a specific therapy. Researchers from Créteil, supported by the AFM-Telethon, in collaboration with two researchers from the institute, have identified a biological marker that could substantially advance research in this field:

  • the rat model of DMD developed in their laboratory (R-DMDdel25) was used,
  • the advantage of this model is that it shows more fibrosis than its mouse counterpart (mdx),
  • the progenitor cells of the adipocyte lineage in this model secrete a high amount of cartilage oligomeric matrix protein (COMP), the level of expression of which is shown to correlate with the degree of muscle fibrosis.


Duchenne muscular dystrophy trajectory in R-DMDdel52 preclinical rat model identifies COMP as biomarker of fibrosis. Taglietti V, Kefi K, Bronisz-Budzyńska I, Mirciloglu B, Rodrigues M, Cardone N, Coulpier F, Periou B, Gentil C, Goddard M, Authier FJ, Pietri-Rouxel F, Malfatti E, Lafuste P, Tiret L, Relaix F. Acta Neuropathol Commun. 2022 Apr 25;10(1):60.